Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIBI-THYR: US + Scintigraphy for Thyroid Nodules
NCT03498183Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- Jan 2019
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial, sponsored by CHU de Nantes. Primary endpoint: Increase in Negative Predictive Value at Month 36. Started Jan 2019; status: completed.
Beyond the preview
Go deeper on NCT03498183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498183.